Arbutus Biopharma (ABUS) Debt to Equity (2016 - 2017)
Arbutus Biopharma's (ABUS) quarterly Debt to Equity came in at $0.07 in Q4 2017, up 11.25% year-on-year from $0.06 in Q4 2016, and down 8.27% quarter-over-quarter from $0.07 in Q3 2017.
Arbutus Biopharma (ABUS) Debt to Equity (2016 - 2017) Analysis & Trends
Arbutus Biopharma has disclosed Debt to Equity across 2 years of filings, most recently posting $0.07 for Q4 2017.
- Debt to Equity for Q4 2017 came in at $0.07, up 11.25% year-over-year; the trailing twelve-month figure through Dec 2017 was $0.07 (up 11.25% YoY), and the FY2017 annual result was $0.07, up 11.25% from the prior year.
- Debt to Equity came in at $0.07 for Q4 2017 at Arbutus Biopharma, down from $0.07 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.07 in Q3 2017 to a low of $0.06 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arbutus Biopharma | 882.62 Mn | 882.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 0.07 |
| Sep 30, 2017 | 0.07 |
| Jun 30, 2017 | 0.07 |
| Mar 31, 2017 | 0.06 |
| Dec 31, 2016 | 0.06 |